| Literature DB >> 31775765 |
Catrin Eriksson1, Matilda Skinstad1, Susanne Georgsson2,3, Tommy Carlsson4,5,6.
Abstract
BACKGROUND: Today, there are various short- and long-acting contraceptive alternatives available for those who wish to prevent unintended pregnancy. Long-acting reversible contraception are considered effective methods with a high user satisfaction. High-quality information about contraception is essential in order to empower individuals to reach informed decisions based on sufficient knowledge. Use of the Web for information about contraception is widespread, and there is a risk that those who use it for this purpose could come in contact with sources of low quality.Entities:
Keywords: Consumer health information; Long-acting reversible contraception; World wide web
Mesh:
Year: 2019 PMID: 31775765 PMCID: PMC6882246 DOI: 10.1186/s12978-019-0835-1
Source DB: PubMed Journal: Reprod Health ISSN: 1742-4755 Impact factor: 3.223
Fig. 1Search process for websites about long-acting reversible contraception
Mean DISCERN scores of the included websites (n = 46) according to source of website and the overall interrater reliability (IRR)
| Subscale | Question [score range] | Government or health care system ( | Pharmaceutical company ( | Independent information website or charity/ organization ( | Overall ( | IRR |
|---|---|---|---|---|---|---|
| Reliability | Clear aims [1-5] | 2.8 (1.5) | 3.2 (0.8) | 2.6 (0.9) | 2.8 (0.9) | 0.11 |
| Achieve aims [1-5] | 3.3 (1.4) | 3.5 (0.9) | 3.0 (0.9) | 3.2 (1.1) | 0.20 | |
| Relevance [1-5] | 3.9 (0.7) | 3.8 (1.0) | 3.1 (0.7) | 3.6 (0.8) | 0.67 | |
| Clear what sources were used [1-5] | 1.1 (0.3) | 1.1 (0.3) | 1.8 (1.1) | 1.3 (0.8) | 0.89 | |
| Clear when the information was produced [1-5] | 1.5 (0.5) | 1.6 (0.5) | 2.3 (0.7) | 1.8 (0.7) | 0.86 | |
| Balanced & unbiased [1-5] | 2.4 (0.5) | 2.2 (0.6) | 2.6 (0.6) | 2.4 (0.6) | 0.37 | |
| Additional sources of support & information [1-5] | 1.7 (0.6) | 1.8 (0.8) | 2.6 (1.5) | 2.1 (1.1) | 0.62 | |
| Refer to areas of uncertainties [1-5] | 2.3 (1.0) | 2.7 (1.2) | 2.6 (0.8) | 2.5 (1.0) | 0.59 | |
| Total score [8-40] | 18.9 (3.7) | 19.1 (3.2) | 20.5 (3.9) | 19.7 (3.7) | 0.43 | |
| Information about long-acting contraceptive choices | How long-acting contraception works [1-5] | 3.9 (0.9) | 3.2 (0.9) | 3.2 (1.2) | 3.4 (1.0) | 0.75 |
| Benefits of long-acting contraception [1-5] | 4.0 (1.1) | 3.9 (1.2) | 3.8 (1.4) | 3.9 (1.2) | 0.62 | |
| Risks of long-acting contraception [1-5] | 4.2 (1.4) | 4.4 (1.2) | 4.2 (1.0) | 4.3 (1.2) | 0.83 | |
| What happen if no long-acting contraception is used [1-5] | 3.0 (1.0) | 2.7 (1.2) | 2.6 (1.1) | 2.8 (1.1) | 0.14 | |
| How long-acting contraception affect overall quality of life [1-5] | 2.5 (0.7) | 2.9 (0.8) | 2.2 (0.5) | 2.5 (0.7) | 0.04 | |
| That there is more than one long-acting contraceptive choice [1-5] | 3.1 (1.4) | 2.5 (1.2) | 3.0 (1.1) | 2.8 (1.2) | 0.78 | |
| Support for shared decision-making [1-5] | 2.6 (0.9) | 2.7 (0.9) | 2.2 (0.8) | 2.5 (0.9) | 0.42 | |
| Total score [7-35] | 23.1 (3.6) | 22.4 (4.5) | 21.2 (4.1) | 22.1 (4.1) | 0.62 | |
| Overall quality | Total score [1-5] | 2.3 (1.2) | 2.3 (1.4) | 2.3 (0.9) | 2.3 (1.1) | 0.53 |
| Total | Total score [16–80] | 44.3 (8.1) | 44.5 (8.2) | 44.0 (7.1) | 44.1 (7.7) | 0.56 |
Fig. 2Distributions of DISCERN scores for the included websites (n = 46) about long-acting reversible contraception (LARC), ranging from 1 (no/low quality) to 5 (yes/high quality)
Proportion of included websites (n = 46) that adhered to the JAMA benchmarks
| Benchmark | Aspects of benchmark disclosed in the web page | Government or health care system, n (%) | Pharmaceutical company, n (%) | Independent information website or charity/organization, n (%) | Total sample, n (%) |
|---|---|---|---|---|---|
| Authorship | Name of author | 9 (69) | 0 (0) | 9 (50) | 18 (39) |
| Author credentials | 9 (69) | 0 (0) | 9 (50) | 18 (39) | |
| Author affiliation | 9 (69) | 0 (0) | 9 (50) | 18 (39) | |
| Adhered to all aspects of benchmark | 9 (69) | 0 (0) | 9 (50) | 18 (39) | |
| Attribution | References | 0 (0) | 1 (7) | 7 (39) | 8 (17) |
| Copyright information | 4 (31) | 11 (73) | 14 (78) | 29 (63) | |
| Adhered to all aspects of benchmark | 0 (0) | 0 (0) | 7 (39) | 7 (15) | |
| Disclosure | Site ownership | 13 (100) | 15 (100) | 15 (83) | 43 (94) |
| Sponsorship, advertising, underwriting, commercial funding arrangements or support | 11 (85) | 4 (27) | 10 (56) | 25 (54) | |
| Conflicts of interest | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Adhered to all aspects of benchmark | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Currency | Date created | 0 (0) | 4 (27) | 9 (50) | 13 (28) |
| Date updated | 7 (54) | 3 (20) | 10 (56) | 20 (44) | |
| Adhered to all aspects of benchmark | 0 (0) | 0 (0) | 1 (6) | 1 (2) |
Identified categories portraying the topics covered in the Swedish websites about long-acting reversible contraception (n = 46)
| Category | n (%) |
|---|---|
| Contraceptive mechanism | 39 (85) |
| Insertion of LARC | 37 (80) |
| Potential adverse reactions, risks and complications | 36 (78) |
| Benefits associated with LARC | 35 (76) |
| Duration of LARC | 34 (74) |
| Configuration and appearance | 34 (74) |
| Contraceptive efficacy | 32 (70) |
| Possible disadvantages of LARC | 30 (65) |
| Expected effects that hormonal LARC has on menstruation | 26 (57) |
| Return of fertility after removal | 23 (50) |
| Removal of LARC | 18 (39) |
| Referral and support for shared decision-making | 17 (37) |
| Use following childbirth and during breast feeding | 16 (35) |
| Associated costs | 13 (28) |
| Actions if pregnancy occurs | 11 (24) |
| Accessibility and which health professionals prescribe LARC | 11 (24) |
| Contraindications | 10 (22) |
| Interactions with other drugs | 7 (15) |
| How it physically feels to have intrauterine LARC in place | 7 (15) |
| Expected effects during the initial period with LARC | 5 (11) |
| How to check position of LARC | 5 (11) |
| When contraception may be initiated following an abortion | 3 (7) |
Readability scores of the included websites (n = 46)
| LIX score | What score represent | Equivalent grade levela | Government or health care system, n (%) | Pharmaceutical company, n (%) | Independent information website or charity/organization, n (%) | Total sample, n (%) |
|---|---|---|---|---|---|---|
| < 25 | Easy-to-read, children’s books | 1–4 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 25–29 | Easy level, fiction | 5–6 | 1 (8) | 0 (0) | 0 (0) | 1 (2) |
| 30–39 | Moderate level, newspapers | 6–8 | 10 (76) | 4 (27) | 3 (17) | 17 (37) |
| 40–49 | Difficult level, official texts | 9–11 | 1 (8) | 10 (66) | 11 (61) | 22 (48) |
| 50–60 | Very difficult level, bureaucratic texts | 11-College | 1 (8) | 1 (7) | 4 (22) | 6 (13) |
| > 60 | Highest difficulty level, dissertations | College | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
a [46]